RAPT RAPT Therapeutics

RAPT Therapeutics to Participate in Upcoming Investor Conferences

RAPT Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in June:

  • Goldman Sachs 46th Annual Global Healthcare Conference – Fireside chat on Tuesday, June 10, 2025 at 9:20 a.m. ET

  • UBS Spring Biotech Conference – Investor one-on-one meetings on Tuesday, June 24, 2025

To access the live webcast or subsequent archived recording of the Goldman Sachs fireside chat, please visit the RAPT Therapeutics website at .

About RAPT Therapeutics, Inc.

RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.

RAPT Investor Contact:

Sylvia Wheeler

RAPT Media Contact:

Aljanae Reynolds



EN
04/06/2025

Underlying

RAPTRAPT Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RAPT Therapeutics

 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics to Participate in Upcoming Investor Conferences

RAPT Therapeutics to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference – Fireside chat on Tuesday, June 10, 2025 at 9:20 a....

June 4, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Reports First Quarter 2025 Financial Results

RAPT Therapeutics Reports First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the first quarter ended March 31, 2025. “The year is off to a great start. We believe RPT904 has the potential to be a best-in-class option to treat patients with food a...

May 8, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointm...

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a n...

April 15, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics to Participate in Upcoming Investor Conferences

RAPT Therapeutics to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March: Leerink Global Healthcare Conference – Fireside chat on Tuesday, March 11, 2025 at 3:40 p.m. ET Bar...

March 7, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ...

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the fourth quarter and year ended December 31, 2024. “Our focus for 2025 will be on advancing development of RPT904, a novel, potential best-in-class ...

March 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch